Oxford, Serum initiative: Anti-malaria vaccine’s Phase 3 trials conclude

The R21 malaria vaccine, which is also known as Matrix-M, was designed at the Jenner Institute, University of Oxford, which collaborated with SII in 2020 to manufacture and develop the jab for large-scale supply.